2026 Q2 Portfolio Activity
In 2026 Q2, Spruce Street Capital LP maintained a portfolio of 33 distinct positions. The most significant new addition was INFLARX NV, now representing 2.35% of the total fund value. They heavily accumulated shares in ALKERMES PLC, increasing the position by 71.0%. Conversely, Spruce Street Capital LP completely exited their position in CENTESSA PHARMACEUTICALS.
Position History
hover any row below to update
Loading…
Spruce Street Capital LP
AUM $510M
Total Positions
33
Quarter
2026 Q2
Top Holding
KNSA (11.5%)
Top 10 Concentration
70.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-33 of 33
Spruce Street Capital LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
KNSA
KINIKSA PHARMAC...
|
Healthcare | 11.52% | 8.81% |
#1
1
Prev: #2
|
8.5 |
—
|
157,007 | 20.6% |
P
S
|
918,070 | $58,710,577 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 10.95% | 7.14% |
#2
3
Prev: #5
|
6.5 |
—
|
no change | no change |
P
S
|
2,984,125 | $55,832,979 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 8.76% | 8.09% |
#3
Prev: #3
|
5.5 |
—
|
no change | no change |
P
S
|
1,376,159 | $44,663,240 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
RLMD
RELMADA THERAPE...
|
Healthcare | 8.68% | 10.34% |
#4
3
Prev: #1
|
4.5 |
—
|
129,214 | 2.1% |
P
S
|
6,391,328 | $44,227,990 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 7.01% | 7.00% |
#5
1
Prev: #6
|
3.8 |
—
|
27,837 | 2.1% |
P
S
|
1,353,047 | $35,706,910 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 6.79% | 7.53% |
#6
2
Prev: #4
|
3.2 |
—
|
-18,458 | -4.9% |
P
S
|
354,816 | $34,587,464 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 5.59% | 2.70% |
#7
7
Prev: #14
|
5.2 |
—
|
225,884 | 71.0% |
P
S
|
543,876 | $28,496,383 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SVRA
SAVARA INC
|
Healthcare | 4.17% | 4.44% |
#8
Prev: #8
|
2.2 |
—
|
69,401 | 2.1% |
P
S
|
3,452,576 | $21,267,868 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 3.49% | 3.43% |
#9
1
Prev: #10
|
3.9 |
—
|
60,338 | 24.6% |
P
S
|
306,047 | $17,790,512 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 3.28% | 3.10% |
#10
1
Prev: #11
|
2.3 |
—
|
no change | no change |
P
S
|
329,006 | $16,697,055 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 3.11% | 2.83% |
#11
2
Prev: #13
|
3.2 |
—
|
156,133 | 16.7% |
P
S
|
1,088,731 | $15,873,698 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 2.47% | 2.63% |
#12
3
Prev: #15
|
3.5 |
—
|
1,066,824 | 40.6% |
P
S
|
3,693,931 | $12,596,305 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IFRX
INFLARX NV
|
Healthcare | 2.35% | — |
#13
Prev: #—
|
4.4 |
—
|
5,352,198 | — |
NEW
|
5,352,198 | $11,988,924 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SRZN
SURROZEN INC
|
Healthcare | 2.20% | 3.03% |
#14
2
Prev: #12
|
1.9 |
—
|
no change | no change |
P
S
|
432,040 | $11,211,438 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ALMS
ALUMIS INC
|
Healthcare | 2.17% | 2.08% |
#15
3
Prev: #18
|
1.9 |
—
|
no change | no change |
P
S
|
392,574 | $11,047,032 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.95% | 2.21% |
#16
1
Prev: #17
|
1.8 |
—
|
no change | no change |
P
S
|
4,059,054 | $9,944,682 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
NERV
MINERVA NEUROSC...
|
Healthcare | 1.80% | 2.40% |
#17
1
Prev: #16
|
1.7 |
—
|
no change | no change |
P
S
|
1,655,500 | $9,188,025 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 1.68% | 2.02% |
#18
1
Prev: #19
|
1.7 |
—
|
no change | no change |
P
S
|
2,198,502 | $8,574,158 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ANTX
AN2 THERAPEUTIC...
|
Healthcare | 1.58% | 1.34% |
#19
4
Prev: #23
|
1.6 |
—
|
no change | no change |
P
S
|
1,661,073 | $8,039,593 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ERAS
ERASCA INC
|
Healthcare | 1.52% | 1.64% |
#20
Prev: #20
|
1.6 |
—
|
no change | no change |
P
S
|
422,543 | $7,740,988 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 1.43% | 1.45% |
#21
Prev: #21
|
1.6 |
—
|
no change | no change |
P
S
|
3,581,603 | $7,270,654 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
RESEARCH ALLIAN...
|
|
Unknown | 1.05% | — |
#22
Prev: #—
|
3.9 |
—
|
500,000 | — |
NEW
|
500,000 | $5,350,000 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 1.04% | 1.22% |
#23
2
Prev: #25
|
1.4 |
—
|
no change | no change |
P
S
|
500,000 | $5,320,000 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
ZLAB
ZAI LAB LTD
|
Healthcare | 1.04% | — |
#24
Prev: #—
|
3.9 |
—
|
279,110 | — |
NEW
|
279,110 | $5,303,090 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ACHV
ACHIEVE LIFE SC...
|
Healthcare | 0.94% | — |
#25
Prev: #—
|
3.9 |
—
|
736,637 | — |
NEW
|
736,637 | $4,810,240 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.85% | 1.28% |
#26
2
Prev: #24
|
1.3 |
—
|
no change | no change |
P
S
|
928,593 | $4,322,600 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.83% | 1.09% |
#27
1
Prev: #26
|
1.3 |
—
|
no change | no change |
P
S
|
2,101,068 | $4,223,147 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
LONA
LEONABIO INC
|
Healthcare | 0.71% | 0.92% |
#28
1
Prev: #27
|
1.3 |
—
|
no change | no change |
P
S
|
393,701 | $3,618,112 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.68% | 0.81% |
#29
1
Prev: #28
|
1.3 |
—
|
no change | no change |
P
S
|
231,585 | $3,459,880 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
N/A
JATT II ACQUISI...
|
|
Unknown | 0.36% | — |
#30
Prev: #—
|
3.6 |
—
|
160,000 | — |
NEW
|
160,000 | $1,817,600 | — | 13F Filing | 2026-06-30 | 2026-08-13 | ||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.00% | 1.44% |
Sold All 😨
(Was: #22) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
KALV
KALVISTA PHARMA...
|
Healthcare | 0.00% | 4.34% |
Sold All 😨
(Was: #9) |
0.0 |
—
|
-897,681 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 0.00% | 4.68% |
Sold All 😨
(Was: #7) |
0.0 |
—
|
-489,849 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-13 |
Showing 1-33 of 33 holdings